Telix Pharmaceuticals (TLX) Assets (2023 - 2026)
Telix Pharmaceuticals (TLX) posted quarterly Assets of $991.7 million for Q4 2024, up 275.25% year-over-year from $264.3 million in Q1 2024, and up 275.25% quarter-over-quarter from $264.3 million in Q4 2023.
Powered by 
Analysis
Telix Pharmaceuticals (TLX) Assets (2023 - 2026) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Assets for 2 consecutive years, with $991.7 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Assets rose 275.25% year-over-year to $991.7 million; the TTM figure through Dec 2024 stood at $991.7 million (up 275.25% YoY), while the FY2024 annual figure was $991.7 million, up 275.25% from the prior year.
- Assets grew to $991.7 million in Q4 2024 per TLX's latest filing, from $264.3 million in the prior quarter.
- Across five years, Assets topped out at $991.7 million in Q4 2024 and bottomed at $264.3 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Telix Pharmaceuticals | 4.03 Bn | 3.74 Bn | - | 1.36 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Bn |
| Dec 31, 2025 | 1.16 Bn |
| Dec 31, 2024 | 991.68 Mn |
| Dec 31, 2023 | 264.27 Mn |